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Abstract
Background—Limited data are available on whether sampling from the penile shaft or urethra
increases detection of penile HPV infection in men beyond that found in the glans and coronal sulcus.
Methods—Within a randomized clinical trial, a validation study of penile sampling was conducted
in Kisumu, Kenya. Young men (18 to 24 years) were invited to provide penile exfoliated cells using
pre-wetted Dacron swabs to determine the best site for HPV detection. β-globin gene PCR and HPV
DNA type GP5+/6+ PCR status were ascertained from three anatomical sites.
Results—A total of 98 young HIV-seronegative, uncircumcised men participated. Penile HPV
prevalence varied by anatomical site: 50% in penile exfoliated cells from the glans, coronal sulcus
and inner foreskin tissue; 43% in the shaft and external foreskin tissue; and 18% in the urethra
(p<0.0001). For each anatomical site, over 87% of samples were β-globin positive. Beyond that found
in the glans/coronal sulcus, urethral sampling resulted in no increase in HPV positivity and shaft
sampling resulted in an additional 7.3% of overall HPV positivity. The prevalence of high-risk HPV
positivity varied by anatomical site: 39% in glans/coronal sulcus, 31% in shaft, and 13% in the urethra
(p<0.0001). HPV 16 was the most common type identified.
Discussion—Penile HPV prevalence was approximately 50% among young men in Kisumu,
Kenya. Urethral sampling for HPV detection in men added no sensitivity for HPV detection over
that found from sampling the glans/coronal sulcus and penile shaft. These data will help inform
studies on HPV transmission dynamics, and on the efficacy of HPV prophylactic vaccines on penile
HPV carriage in men.
Summary—A validation study of penile sampling was conducted among young, uncircumcised
men in Kenya and found that overall penile HPV DNA prevalence was approximately 50%. Beyond
that found in the glans/coronal sulcus, urethral sampling resulted in no increase in HPV positivity
and shaft sampling resulted in an additional 7.3% of overall HPV positivity.
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Years before human papillomavirus (HPV) infection was identified as the cause of invasive
cervical cancer (ICC) in women (1), men were considered important in the etiology of ICC
(2-3). Penile cancer rates have been correlated with ICC rates in women on the population-
level (2) and a 4-fold increased risk of cervical cancer was found among women whose
husbands had been previously married to a woman with cervical cancer (3). Given that men
may transmit HPV infection to their female sexual partners, data on the prevalence of penile
HPV infections in men and on transmission of HPV between sexual partners are needed to
inform future cervical cancer prevention strategies, including the use of prophylactic HPV
vaccines.
In determining the prevalence of genital HPV infections using highly-sensitive PCR-based
laboratory detection, relatively few studies have been conducted in men as compared to women.
The lack of studies on penile HPV infection has been due in part to the difficulty in identifying
the most reliable sampling method and site to collect genital specimens in men. Recent PCR-
based studies have increased our understanding of the burden of HPV infections in men by
allowing identification of asymptomatic infections. We are no longer limited to the detection
of clinical HPV-associated penile lesions using visual penoscopic inspection, or relatively
insensitive detection methods (e.g. in-situ hybridization) (4-6). Sampling of penile exfoliated
cells for HPV detection in most studies of men has been from the glans/coronal sulcus and
sometimes urethra, generally without sampling from other penile anatomical sites (7;8).
Limited data are thus available on whether sampling from penile sites other than the glans and
coronal sulcus, such as the penile shaft, might increase detection of penile HPV infection in
men (8;9) and whether this would impact HPV prevalence estimates for circumcised and
uncircumcised men.
In the framework of a randomized clinical trial (RCT), a validation study of penile sampling
was conducted in Kisumu, Kenya. Young, uncircumcised, HIV-seronegative men were asked
to provide penile exfoliated cell samples to determine the best anatomical site for penile HPV
detection.
Methods
Study population and enrollment
Uncircumcised men aged 18 to 24 years of age in Kisumu, Kenya were invited between
February 4, 2002 and September 6, 2005 to participate in a randomized clinical trial (RCT) of
male circumcision, coordinated by the Universities of Illinois at Chicago, Nairobi and
Manitoba and RTI International. The primary aim of this RCT is to determine the effectiveness
of male circumcision in reducing HIV incidence. Inclusion criteria included being
uncircumcised, HIV seronegative, sexually active (defined as reporting sex within the last 12
months), and having hemoglobin ≥ 9.0 grams/100 ml. Men were excluded if their foreskin did
not cover one-half or more of their glans, if they were not a resident in Kisumu or surroundings,
were unlikely to remain in the study region for the 2-year follow-up period, or were unwilling
to conform to the study follow-up protocol. Other exclusion criteria included hemophilia, other
bleeding disorders, medical conditions for which a surgical procedure was contra-indicated,
hypospadius, or an absolute indication for circumcision (e.g. urinary retention).
Male study participants were recruited from sexually transmitted infection (STI) clinics,
workplaces, and community organizations. Most recruits were young men with high to
moderate sexual risk-behavior. This HPV study is based on early participants to the randomized
clinical trial who consented to HPV sample collection and shipment oversees for storage and
tests. Inclusion required that baseline samples be available for shipment to the HPV DNA
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laboratory by mid-March, 2002. Specifically, between February 4 and March 7, 2002, 188 men
completed an initial screening to participate in the RCT. Of these, 126 men eventually met
inclusion criteria for the trial (HIV-seronegative, uncircumcised, sexually active, aged 18-24
years, having a hemoglobin of 9.0 grams per ≥ 100 ml, and a Kisumu resident) and were
randomized. 115 of the 126 men had an enrollment visit by mid-March 2002 when HPV
samples were shipped. Among the 115 men, 99 consented to HPV sample collection and
shipment overseas for storage and HPV testing. One of these 99 individuals was subsequently
excluded from the HPV study due to improper specimen collection.
The study protocol was reviewed and approved by the Institutional Review Boards of the
Universities of Illinois at Chicago, Manitoba, Nairobi and North Carolina; RTI International
and the VU University Medical Center.
Questionnaire, clinical examination and specimen collection
After undergoing informed consent, study participants were administered a standardized
questionnaire on sociodemographic characteristics, and sexual behavior, by a trained male
interviewer.
Participants also underwent a clinical examination by a trained physician or clinical officer.
Penile exfoliated cells were collected for HPV DNA detection from three anatomical sites using
pre-wetted Dacron swabs in separate conical tubes: shaft and external foreskin tissue (shaft
specimen), the glans, coronal sulcus and inner foreskin tissue (glans specimen); and the urethra.
Shaft and external foreskin cells were collected from each of the four sides of the external shaft
tissue, from the proximal to distal penile shaft, using a type 3 Dacron swab pre-wetted in Tris
buffer. From the glans and coronal sulcus, a second pre-wetted Type 3 Dacron swab was used
as follows: the prepuce was gently retracted to collect exfoliated cells by swabbing the tip of
the urethral opening, completely circling the urethral orifice 2-3 times; sampling the top to the
bottom of the glans in a circular motion around the complete circumference of the penis;
rotating the swab three times completely around the circumference of the coronal sulcus; and
sampling from the inner foreskin tissue. A sample of the outer, external surface of the foreskin
was also included in the glans sample as funding was not sufficient to test this specimen
separately. A third specimen was collected from the distal urethra using a pre-wetted Type 1
Dacron swab, which was inserted approximately 2 cm into the urethra.
All three penile cell samples were placed in individual 15 ml centrifuge tubes containing 2 ml
10mM Tris-HCl, 0.01M 7.4 pH, buffer, and processed on the day of collection at the UNIM
(Universities of Nairobi, Illinois and Manitoba) clinic laboratory by centrifugation at high
speed (maximum, 3000 g) for 10 minutes. Excess Tris-HCl buffer was discarded using a
Pasteur pipette, and the remaining cell pellet was resuspended in the same volume of 0.1 mM
Tris-HCl buffer, and vortexed. Diluted cell pellets were then frozen at -75°C. All samples were
sent using a dry shipper to the Department of Pathology, VU University Medical Center,
Amsterdam, the Netherlands for HPV DNA laboratory testing.
HPV DNA testing
Crude extracts of penile exfoliated cell pellets obtained by consecutive freeze-thaw and boiling
steps were evaluated for DNA quality by beta (β)-globin specific PCR followed by agarose
gel electrophoresis according to protocols that have been detailed elsewhere (10-12). Of
samples that were β-globin PCR negative on the crude extracts, the β-globin PCR was repeated
following isolation of nucleic acids using magnetic beads and an EasyMag (Biomerieux)
extractor. The samples that were β-globin PCR negative on isolated DNA as well were
considered β-globin negative in this study. Of those that were β-globin PCR positive on the
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isolated DNA only, the DNA rather than the crude extract was used for subsequent HPV PCR
analysis.
HPV positivity was assessed by GP5+/6+ PCR and an enzyme immunoassay (EIA) read-out
system coupled thereto that, using HPV oligoprobe cocktails, detects the following 37 HPV
types: HPV 6, 11, 16, 18, 26, 31, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 55, 56, 57,
58, 59, 66, 68, 61, 67, 70, 71 (equivalent to CP8061), 72, 73, 81 (equivalent to CP8304), 82
(IS39 and MM4 subtypes), 83 (equivalent to MM7), 84 (equivalent to MM8) and CP 6108
(10). Cycling and staining conditions were as described before (11)(12)
Subsequently, GP5+/6+-PCR positive samples were subjected to HPV typing by reverse line
blot hybridization (11;12). HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, and
73 were considered high-risk (HR) types. The group of low-risk (LR) types included all other
HPV types tested. HPV infections with more than one HPV type were considered as high-risk
if any HPV type detected was high-risk.
Statistical methods
Associations between categorical variables were assessed nonparametrically using Mantel-
Haenszel (MH) methods to account for multiple measures from each study participant for the
three anatomical sites (13). For example, a MH test for general association with stratification
by participant was used to assess differences in HPV DNA positivity by anatomical sampling
site. All MH tests were stratified by participant unless noted otherwise.
To determine possible factors associated with site-specific HPV infection, odds ratios (ORs)
for HPV DNA detection and corresponding 95% confidence intervals (CIs) were estimated
using logistic regression for each combination of site and possible risk factor. Logistic
regression models were also employed to assess association between possible risk factors and
overall HPV status wherein participants were categorized as positive if HPV infection was
detected at one or more sites. All models included age as a covariate. No multiple comparison
adjustments were made. Analyses were conducted using SAS (13)and R (14).
Results
β-globin and HPV prevalence, by anatomical collection site
A total of 98 uncircumcised men participated (median reported age=22, range=17-25). HPV
prevalence varied by anatomical site (Table 1): 50% in penile exfoliated cells from the glans,
43% from the shaft, and 18% from the urethra (p<0.0001, MH test). β-globin positivity ranged
from 88% in the shaft to 100% in the urethra (p=0.002, MH test). For β-globin positive samples,
HPV DNA positivity was significantly lower in urethral than in the glans and in the shaft
(p<0.0001, MH test). Analyses excluding urethral samples indicated no significant difference
between glans and shaft sites in HPV prevalence (p=0.07, MH test), β-globin positivity
(p=0.13, MH test), or HPV prevalence conditional on β-globin positivity (p=0.08, MH test).
For β-globin negative samples, the observed prevalence was 33% for both the glans and shaft.
In absolute terms, HPV DNA positivity was higher in β-globin positive samples compared to
β-globin negative samples for both the glans and shaft (p=0.27, MH test stratified by sampling
site). All subsequent analyses were thus limited to β-globin positive samples.
Samples from all three sites were β-globin positive for 81 participants. Of these men, 44 were
HPV positive in at least one site (Table 2), representing a 54% HPV positivity overall. For men
who were HPV positive in at least one site, N=41 were HPV positive in the glans (93% of
overall HPV positives), N=35 were HPV positive in the shaft (80% of overall HPV positives)
and N=17 were HPV positive in the urethra (39% of overall HPV positives). No samples were
found to be HPV positive in the urethra that were not positive in either the glans or shaft. Shaft
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sampling resulted in an additional 7.3% of overall HPV positivity beyond that found in the
glans/coronal sulcus.
HPV type-specific distribution
A total of 29 different HPV types (15 high-risk and 14 low-risk) were detected in either single
or multiple infections (Figure 1). Most HPV-positive men had at least one high-risk HPV type
detected (ranging from 71% in the shaft to 77% in the glans). Overall, the prevalence of high-
risk infections varied by anatomical site: 39% in the glans, 31% in the shaft, and 13% in the
urethra (p<0.0001, MH test). The prevalence of low-risk infections also varied by site: 12% in
the glans, 13% in the shaft, and 5% in the urethra (p=0.02, MH test). Similarly, the prevalence
of multiple HPV infections varied by site: 34% in the glans, 29% in the shaft, and 8% in the
urethra (p<0.0001, MH test). Of note, over half of the 29 HPV types detected (52%) were found
only within multiple infections, including high-risk HPV types 18, 31, 33, 39, 45, 52, 68, 73,
and low-risk HPV types 26, 53, 55, 67, 72, 81, and CP6108. High-risk HPV type 16 was the
most common type detected in all three sites: 13% of glans samples, 12% of shaft samples and
4% of urethra samples (types 56 and 58 also occurred in 4% of the urethra samples).
Figure 2 compares the observed HPV type-specific prevalence between each of the two pairs
of the three sites. Overall, HPV positivity in the glans is close to the line of agreement with
that detected from the shaft (Figure 2b). HPV 45 was more prevalent in the shaft than the glans
whereas types 35, 58 and 52 were more likely detected in the glans than shaft. Two multiple
(HPV 31/45, HPV 40/51/58/70) and one single (HPV 83) HPV infection were found in three
shaft specimens that were HPV negative in the corresponding glans specimen. No additional
HPV types were detected from the urethra that were not already detected in one or more of the
remaining sites sampled as shown in Figures 2a and 2c.
Sample pooling
To determine whether the samples from the shaft and glans could be pooled (combined) for
PCR purposes without losing information about β-globin or HPV status, we examined 41
combined samples (data not shown). Among 23 samples that were HPV positive on both the
shaft and glans before pooling, all were HPV positive in the pooled sample. However, the
pooled samples had consistently fewer detectable HPV types when compared to the results of
adding the-globin positive after pooling. Among the 9 samples with discrepant HPV results
before pooling, all were HPV DNA positive after pooling. Thus, PCR testing could be
performed on pooled samples of the shaft and glans to obtain a reliable measurement of overall
HPV positivity, but not to obtain reliable results on HPV type distribution.
Risk factors for penile HPV infection
The absolute prevalence of penile HPV DNA was higher in men of age in all three anatomical
collection sites, although a significant association was only found in the glans (OR=2.7; 95%
CI: 1.1-6.8). Trends towards increased overall prevalence of penile HPV positivity overall were
noted with increasing number of reported lifetime sexual partners (OR=1.8, 95% CI: 0.5-5.8
for 3-5 partners, OR=2, 95% CI: 0.5-7.5 for 6 or more partners) and total number of sexual
partners in the last 12-months (OR=2.2, 95% CI: 0.5-10 for 1 partner, OR=5.3, 95% CI: 1.2-24
for 2 or more partners). A trend towards lower overall HPV prevalence was observed with a
history of condom use in the last 6-months with significant protection noted for consistent
condom use (OR=0.74, 95% CI: 0.19-2.9 for use ≤ 50% of the time; OR=0.26, 95% CI: 0.08-0.9
for use >50% of the time). A non-significant trend of lower overall HPV prevalence was also
noted with condom use with the last sexual partner (OR=0.6, 95% CI: 0.25-1.5). HPV positivity
also tended to be more frequent among participants reporting lower educational attainment
(OR= 0.11, 95% CI: 0.02-0.6 for secondary versus primary; OR=0.14, 95% CI: 0.02-1.1 for
tertiary versus primary). Young men who reported to be salaried had a higher absolute HPV
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positivity in all three sites than those who were unemployed, although associations were only
significant in shaft specimens (OR=4.4; 95% CI: 1.2-15). Penile HPV DNA detection did not
appear to be associated with age at first intercourse or marital status (data not shown) (Table
3).
Discussion
This is a unique study which reports data on HPV infection among healthy uncircumcised men
from Africa, and includes a comparison of individual, type-specific HPV DNA positivity at
different anatomical sites. Penile HPV prevalence has varied notably across studies of young
men using sensitive PCR-based methods, ranging from 1 to 73% (6;15-20). In comparison, the
overall HPV positivity in the current study was relatively high (54%). The current study’s
results are consistent with that found among sexually active males (20-29 years) from
Cuernavaca, Mexico (50%) (16) and soldiers aged 21-24 in Mexico City (48.6%)(17), and
higher than that found in similarly-aged university students in Seattle(35%)(9) and Korea
(8.7%)(20), or in military conscripts from Finland (9.1%)(18) or Sweden (12%)(19). Reliable
comparisons of the penile HPV prevalence across studies, however, are hampered by
differences in populations surveyed, in anatomical sites sampled, in HPV DNA detection
assays, and possibly in circumcision status.
In this study, β-globin positivity was high in specimens obtained using pre-wetted swabs from
the glans/coronal sulcus (94%), shaft (87%) and urethra (100%). Although sampling of genital
sites for HPV using emery paper has been successfully used by other US groups (9;21), the
use of emory paper in this Kenyan population was not considered culturally acceptable. A
strength of our study is that we were able to obtain a high β-globin positivity rate using a pre-
wetted swabs alone. β-globin positivity based on sampling with a pre-wetted Dacron swab, has
ranged from 74 to 100% in previous studies in men (6;7;22).
A low HPV DNA yield was obtained from urethral sampling. These results are consistent with
a previous study of 820 Mexican soldiers, which concluded that urethral sampling did not
markedly increase overall HPV positivity beyond that found in the glans/coronal sulcus (8).
Taken together, these data consistently suggest that sampling from the urethra in men results
in adequate cell yield, but a low sensitivity for HPV detection. Since no additional HPV
infections are detected by urethral sampling, and since asymptomatic men tend not to agree to
urethral sampling due to discomfort, urethral sampling should not be considered necessary for
optimal penile HPV detection protocols.
Similar HPV DNA detection rates were found in penile exfoliated cells collected from the glans
than in the penile shaft among young Kenyan men. The addition of the shaft specimen did not
statistically increase overall HPV DNA detection rates beyond that found in the glans and
coronal sulcus alone. However, the inclusion of the shaft specimen permitted the detection of
three additional HPV positive samples (equating to 6.8% of HPV positive cases). These results
are consistent with a previous study of 50 uncircumcised male university students in Seattle
that found that 5.6% of HPV infections found in either the glans, foreskin or shaft would have
been missed if shaft sampling had not been done(9). By comparing HPV type-specific detection
rates by anatomical sites, data from this present study suggest an improved detection of
carcinogenic HPV type 45 by the inclusion of shaft sampling in men, when compared to routine
sampling of solely the glans and coronal sulcus.
High-risk HPV type 16 was the most common type detected in the current study, which is
consistent with other studies in men from Sweden (23) and from a pooled analysis of men from
Brazil, Colombia, Thailand, Philippines and Spain (7). In contrast, HPV type 59 was the most
commonly detected type among men in two studies from Mexico (8;17). Among HPV positive
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men, data from the current study suggest that the prevalence of high and of low-risk HPV types
in the shaft was similar to that found in the glans/coronal sulcus. These results are generally
consistent with Mexican data suggesting that HPV types found in HPV DNA positive men did
not notably differ by site of cell collection (glans/coronal sulcus, shaft, urethra)(17).
Results from our pilot study pooling samples from the shaft and glans/sulcus found that PCR
testing can be performed on pooled samples in order to obtain a reliable measurement of overall
HPV positivity, but not to obtain reliable results on HPV type-specific distribution. Given the
high prevalence of penile HPV (∼50%) in this validation study, the pooling of samples was
not considered efficient for penile HPV ascertainment in this cohort.
Younger age (≤21), lower educational status, and being salaried were consistently associated
with a higher prevalence of penile HPV positivity in the three sampling sites, although our
sample size was too small to detect meaningful differences. Our analyses also suggested a
lower prevalence of HPV infection among male participants who reported consistent condom
use, and fewer sexual partners, consistent with previous studies that have shown that markers
of sexual behavior, such as lifetime and recent sexual partners, are associated with HPV
infection prevalence(6;24). Penile HPV risk factors in this study appeared similar for samples
collected from the glans/coronal sulcus and the shaft.
The current study’s advantages include the inclusion of uncircumcised men from a unique
Kenyan population at a high-risk of HPV infection and central, type-specific DNA testing with
an experienced HPV DNA laboratory using a highly sensitive, GP5+/6+ detection assay. Study
limitations include not collecting male samples from either the scrotum or urine, although
previous research suggests that sampling from either one of these sites is unlikely to result in
higher HPV DNA positivity beyond that found in the penile shaft, glans coronal sulcus and
inner foreskin tissue(9). Our data are also limited to uncircumcised men. Sampling from the
shaft may notably increase HPV detection rates beyond the glans in circumcised men more
than in uncircumcised men (9). Further comparisons of β-globin and HPV positivity among
both circumcised and uncircumcised men, stratified by glans or shaft sampling, are planned in
future study follow-up.
With recent improvements in the validity and range of sampling methods for HPV
ascertainment in men, it will be possible to evaluate the potential efficacy of HPV prophylactic
vaccines on penile HPV carriage in men and on HPV transmission dynamics between sexual
partners using highly sensitive detection assays.
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Horizontal barplots of percent HPV positive among β-globin positive samples by anatomical
site (G=glans, S=Shaft, U=Urethra) for different HPV types. For example, the upper left panel
gives the percent HPV positive to at least one high-risk HPV type, with 13% of urethra samples
positive, 32% of shaft samples positive, and 39% of glans samples positive. Dark shading
indicates infection with multiple HPV types; light shading denotes infection with a single HPV
type.
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Scatterplots of percent HPV positive among β-globin positive samples across anatomical sites
by HPV type. The gray diagonal line indicates perfect agreement in percent HPV positive
between the two corresponding sites. High-risk HPV types are in bold.
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Table 2
Penile human papillomavirus (HPV) by anatomical site for young men in Kisumu, Kenya with β-globin positive
samples from all three sites
Shaft Glans Urethra N %
- - - 37 45.7
+ + + 16 19.8
+ + - 16 19.8
- + - 8 9.9
+ - - 3 3.7
- + + 1 1.2
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